Dr. Reddy's Laboratories Limited Statistics
Share Statistics
Dr. Reddy's Laboratories Limited has 833.03M shares outstanding. The number of shares has increased by 0.04% in one year.
Shares Outstanding | 833.03M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0.02% |
Owned by Institutions (%) | n/a |
Shares Floating | 833.01M |
Failed to Deliver (FTD) Shares | 195 |
FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 10.68M, so 1.28% of the outstanding shares have been sold short.
Short Interest | 10.68M |
Short % of Shares Out | 1.28% |
Short % of Float | 1.28% |
Short Ratio (days to cover) | 12.83 |
Valuation Ratios
The PE ratio is 18.68 and the forward PE ratio is 16.98. Dr. Reddy's Laboratories Limited's PEG ratio is 2.63.
PE Ratio | 18.68 |
Forward PE | 16.98 |
PS Ratio | 3.73 |
Forward PS | 0 |
PB Ratio | 3.71 |
P/FCF Ratio | 57.79 |
PEG Ratio | 2.63 |
Enterprise Valuation
Dr. Reddy's Laboratories Limited has an Enterprise Value (EV) of 783.74B.
EV / Earnings | 14.07 |
EV / Sales | 2.81 |
EV / EBITDA | 8.86 |
EV / EBIT | 11.57 |
EV / FCF | 43.55 |
Financial Position
The company has a current ratio of 2.58, with a Debt / Equity ratio of 0.06.
Current Ratio | 2.58 |
Quick Ratio | 1.92 |
Debt / Equity | 0.06 |
Total Debt / Capitalization | 5.56 |
Cash Flow / Debt | 2.75 |
Interest Coverage | 39.58 |
Financial Efficiency
Return on equity (ROE) is 0.2% and return on capital (ROIC) is 17.46%.
Return on Equity (ROE) | 0.2% |
Return on Assets (ROA) | 0.14% |
Return on Capital (ROIC) | 17.46% |
Revenue Per Employee | 10.32M |
Profits Per Employee | 2.06M |
Employee Count | 27.05K |
Asset Turnover | 0.72 |
Inventory Turnover | 1.82 |
Taxes
Income Tax | 16.19B |
Effective Tax Rate | 0.23 |
Stock Price Statistics
The stock price has increased by 8.56% in the last 52 weeks. The beta is 0.33, so Dr. Reddy's Laboratories Limited's price volatility has been higher than the market average.
Beta | 0.33 |
52-Week Price Change | 8.56% |
50-Day Moving Average | 14.94 |
200-Day Moving Average | 15.13 |
Relative Strength Index (RSI) | 46.54 |
Average Volume (20 Days) | 953.27K |
Income Statement
In the last 12 months, Dr. Reddy's Laboratories Limited had revenue of $279.16B and earned $55.68B in profits. Earnings per share was $334.02.
Revenue | 279.16B |
Gross Profit | 163.61B |
Operating Income | 67.73B |
Net Income | 55.68B |
EBITDA | 88.42B |
EBIT | 67.73B |
Earnings Per Share (EPS) | 334.02 |
Balance Sheet
The company has $7.11B in cash and $20.02B in debt, giving a net cash position of -$12.91B.
Cash & Cash Equivalents | 7.11B |
Total Debt | 20.02B |
Net Cash | -12.91B |
Retained Earnings | 265.26B |
Total Assets | 465.95B |
Working Capital | 118.83B |
Cash Flow
In the last 12 months, operating cash flow was $45.43B and capital expenditures -$27.43B, giving a free cash flow of $18.00B.
Operating Cash Flow | 45.43B |
Capital Expenditures | -27.43B |
Free Cash Flow | 18.00B |
FCF Per Share | 21.63 |
Margins
Gross margin is 58.61%, with operating and profit margins of 24.26% and 19.95%.
Gross Margin | 58.61% |
Operating Margin | 24.26% |
Pretax Margin | 25.74% |
Profit Margin | 19.95% |
EBITDA Margin | 31.67% |
EBIT Margin | 24.26% |
FCF Margin | 6.45% |
Dividends & Yields
RDY pays an annual dividend of $0.96, which amounts to a dividend yield of 6.67%.
Dividend Per Share | $0.96 |
Dividend Yield | 6.67% |
Dividend Growth (YoY) | -1.57% |
Payout Ratio | 123.08% |
Earnings Yield | 2309.96% |
FCF Yield | 149.36% |
Analyst Forecast
The average price target for RDY is $17, which is 17.6% higher than the current price. The consensus rating is "Buy".
Price Target | $17 |
Price Target Difference | 17.6% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Stock Splits
The last stock split was on Nov 5, 2024. It was a forward split with a ratio of 5:1.
Last Split Date | Nov 5, 2024 |
Split Type | forward |
Split Ratio | 5:1 |
Scores
Altman Z-Score | 2.35 |
Piotroski F-Score | 5 |